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O B J E C T I V E S The goal of this study was to develop and validate a new ﬁbrin-targeted imaging agent
that enables high-resolution near-infrared ﬂuorescence (NIRF) imaging of deep vein thrombosis (DVT).
B A C KG ROUND NIRF imaging of ﬁbrin could enable highly sensitive and noninvasive molecular
imaging of thrombosis syndromes in vivo.
METHOD S A ﬁbrin-targeted peptidewas conjugated to a near-infrared ﬂuorophore Cy7, termed FTP11-Cy7.
The NIRF peptide is based on a ﬁbrin-speciﬁc imaging agent that has completed Phase II clinical magnetic
resonance imaging trials. In vitro binding of FTP11-Cy7 to human plasma clots was assessed by using ﬂuorescence
reﬂectance imaging. Next, FTP11-Cy7was intravenously injected inmicewith femoral DVT inducedby topical 7.5%
ferric chloride treatment. Intravital ﬂuorescencemicroscopy andnoninvasive ﬂuorescencemolecular tomography–
computed tomography were performed in 32 mice with DVT, followed by histological analyses.
R E S U L T S In vitro human clot-binding analyses showed a 6-fold higher NIRF clot target-to-background
ratio (TBR) of FTP11-Cy7 than free Cy7 (6.3 0.34 vs. 1.2 0.03; p 0.0001). The thrombus TBR of acute and
subacute femoral DVT with FTP11-Cy7 obtained by using intravital ﬂuorescence microscopy was 400%
higher than control free Cy7. Binding of FTP11-Cy7 to thrombi was blocked by a 100-fold excess of unlabeled
competitor peptide both in vitro and in vivo (p  0.001 for each). Histological analyses conﬁrmed that
FTP11-Cy7 speciﬁcally accumulated in thrombi. Noninvasive ﬂuorescence molecular tomography–computed
tomography imaging of ﬁbrin in jugular DVT demonstrated strong NIRF signal in thrombi compared with
sham-operated jugular veins (mean TBR 3.5  0.7 vs. 1.5  0.3; p  0.05).
CONC L U S I O N S The ﬁbrin-targeted NIRF agent FTP11-Cy7 was shown to avidly and speciﬁcally
bind human and murine thrombi, and enable sensitive, multimodal intravital and noninvasive NIRF
molecular imaging detection of acute and subacute murine DVT in vivo. (J Am Coll Cardiol Img 2012;
5:607–15) © 2012 by the American College of Cardiology Foundation
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hrombosis and thromboembolic diseases
such as myocardial infarction, stroke, pulmo-
nary embolism, and deep vein thrombosis
(DVT) are major causes of morbidity and
ortality worldwide (1). Clinical detection of
hrombosis syndromes often uses ultrasound, x-ray
omputed tomography (CT), or magnetic reso-
ance imaging (MRI). However, such imaging
pproaches require the presence of a relatively large
hrombus to render a diagnosis of a thrombotic
isorder. In many cases (e.g., plaque rupture, stent
hrombosis, early or resolving DVT), a much more
See page 616
sensitive measure of early thrombosis is
required. Furthermore, thrombus detec-
tion for most current imaging modalities is
structurally related to the cessation of
blood flow. It could therefore prove ben-
eficial to harness a molecular marker of
fibrin to characterize thrombus or micro-
thrombus type/composition and to guide
fibrinolytic therapy of fibrin-rich thrombi.
Fibrin, a trimeric molecule consisting of
alpha-, beta-, and gamma-chains, is pres-
ent in both arterial and venous thrombi at
micromolar concentrations and is mini-
mally present in the circulating blood,
rendering it a favorable imaging target for
in vivo detection (2). Previous studies have
investigated fibrin-targeted agents for nu-
clear imaging (3,4) and more recently, a
fibrin-specific gadolinium-based agent
(EP-2104R) for MRI (5-8) that has been
tested in clinical trials (9,10).
However, only a few robust fibrin-
targeted agents exist for in vivo optical,
and specifically, near-infrared fluorescence
(NIRF), imaging. Attractive features of NIRF im-
aging include high-resolution imaging capabilities
(11), as well as noninvasive (12) and intravascular (13,14)
imaging platforms. In addition, fluorescence-based de-
tection is inherently more sensitive than MRI-based
detection and thus requires lower dosages and shorter
washout times for injected agents (15).
In this study, we synthesized and investigated the
avidity and specificity of a new fibrin-targeted
NIRF thrombus imaging agent termed FTP11-
Cy7. We report here the targeting capabilities and
specificity of the NIRF agent in acute and subacute
murine DVT by using high-resolution intra-vital
y
s
lar
ce
cefluorescence microscopy (IVFM) and noninvasiveintegrated fluorescence molecular tomography
(FMT)–computed tomography (CT) in vivo.
M E T H O D S
Synthesis of FTP11-Cy7, a NIRF ﬁbrin-targeted imaging
agent. The fibrin-targeted fluorescent peptide
(FTP11-Cy7) was synthesized in the MGH Peptide/
Protein Core facility using solid-phase chemistry-
based on EP-2104R (8), a peptide imaging agent
omprising 11 amino acids (Tyr-D-Glu-Cys-Hyp-
yr [3-Cl]-Gly-Leu-Cys-Tyr-Ile-Gln-NH2), and
cyclized via the formation of a disulphide bond (8).
Full synthesis details are provided in the Online
Appendix. Linearity of the NIRF signal intensity
generated from FTP11-Cy7 was assessed by using
fluorescence reflectance imaging (FRI) at various
concentrations (sample volume of 50 l).
In vitro clot binding. Human plasma clots were
reated from fresh-frozen plasma (FFP) in 96 well
lates (16). FFP was obtained using an institutional
eview board–approved human subject protocol.
ach well received 90 l of FFP, 5 l of 0.4 M
aCl2, and 5 l of thrombin (0.1 U/l phosphate-
buffered saline [PBS]). The plate was incubated at
37°C for 90 min to clot the plasma. Thereafter, 0.02
nmol of fluorophore was added to respective wells
and then incubated at 37°C for an additional 30
min. In competitive binding assays, unlabeled
FTP11 at 10-fold or 100-fold excess concentration
was added 30 min before the incubation of FTP11-
Cy7 with clots. The clots were then washed twice
with PBS and centrifuged at 500 rpm for 10 min.
They were then washed twice more with PBS and
imaged by using FRI (excitation/emission 740/790
nm). Experiments were performed in quadruplicate.
Animal studies. Animal studies were approved by
he Hospital Subcommittee of Research Animal
are. For in vivo studies, C57BL/6 mice were anes-
hetized using an intraperitoneal ketamine (50 mg/ml
330 l]), xylazine (100 mg/ml [50 l]), and sterile
aline (380 l) mixture. Each mouse received a 50-l
intraperitoneal induction dose of the resulting mix-
ture, followed by a 10- to 20-l intraperitoneal dose
hourly for continued anesthesia.
Blood half-life study of FTP11-Cy7. To determine the
lood half-life of FTP11-Cy7, serial blood sam-
ling was performed through a jugular vein.
57BL/6 mice (n  5) received a 150 nmol/kg
intravenous bolus of the FTP11-Cy7 dissolved in
PBS. At the desired time points, a 50-l volume of
lood was obtained and mixed with 50 l ofA B B R E V I A T I O N S
A N D A C R O N YM S
CT computed tomograph
DVT deep vein thrombosi
FFP fresh-frozen plasma
FITC fluorescein
isothiocyanate
FMT fluorescence molecu
tomography
FRI fluorescence reflectan
imaging
IVFM intravital fluorescen
microscopy
MRImagnetic resonance
imaging
NIR near-infrared
NIRF near-infrared
fluorescence
PBS phosphate-buffered
saline
TBR target-to-backgroundheparin (1,000 USP units/ml) and kept on ice until
d
f
a
i
5
a
r
d
i
F
m
I
(
S
4
i
m
T
i
4
p
w
i
b
c
t
e
M
o
t
(
N
a
d
t
P
a
P
c
s
v
a
b
w
e
C
M
i
fi
(
w
2
T
d
o
m
a
O
t
d
b
g
o
fl
s
m
f
a
E
w
(
5
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 6 , 2 0 1 2
J U N E 2 0 1 2 : 6 0 7 – 1 5
Hara et al.
NIRF Molecular Imaging of Fibrin-Rich DVT
609analysis. The Cy7 fluorescence of the blood at each
time point was quantified by using FRI. The blood
NIRF signal at each time point was measured and
then normalized by the NIRF signal at 1 min
post-injection. Exponential fitting yielded the
blood half-life of FTP11-Cy7 (GraphPad Prism
5.0, San Diego, California).
Creation of DVT in mice. In vivo DVT were induced
by topical ferric chloride injury to the femoral vein
(for IVFM studies) or jugular vein (for FMT
studies) (17). Under anesthesia, ferric chloride was
locally applied to the vein using a 1-mm strip of
Whatman No. 1 filter paper soaked in 7.5% ferric
chloride. The filter paper was applied to the anterior
surface of the vein for 5 min. Thereafter, the filter
paper was removed, and the surgical field was
irrigated with PBS. For acute imaging studies,
imaging was performed in 2-h-old DVT. For
subacute imaging studies, imaging was performed
in 3-day-old (72-h) DVT. A total of 32 mice were
studied.
Intravital ﬂuorescence microscopy. To image fibrin
eposition in thrombi at high-resolution, IVFM of
emoral DVT was performed in 23 mice. Mice were
nesthetized as noted earlier. At 60 min before
maging, a fibrin-targeted agent (FTP11-Cy7, n 
acute DVT; n  5 subacute DVT) or control
gent (free Cy7, n  5) was administered via
etro-orbital injection. Agents were injected at a
ose of 150 nmol/kg in 100 l of total volume. In
n-vivo blocking experiments (n  8), unlabeled
TP11 (1,500 nmol/kg) or PBS was injected 30
in before injection of FTP11-Cy7 (15 nmol/kg).
njection of 100 l of fluorescein-labeled dextran
fluorescein isothiocyanate [FITC]-dextran, Sigma,
t. Louis, Missouri; 5 mg/ml; excitation/emission
90/520 nm) provided an angiogram. IVFM stud-
es used a multichannel laser scanning fluorescence
icroscope optimized for intravital imaging (18).
he utilized 30 objective (NA 0.9) provided an
n-plane resolution of 1.4 m/pixel. Z stacks (20 to
0 slices) were obtained at 5-m steps through the
vessel. All image settings were kept constant for all
time points and samples.
FMT-CT. Noninvasive integrated FMT-CT was
erformed as previously described (19) in 9 mice
ith subacute jugular vein DVT. FTP11-Cy7 was
njected intravenously at 150 nmol/kg mouse 1 h
efore imaging. The surgical incisions remained
losed during imaging. The NIRF signal was de-
ected with a FMT 2500 system (excitation/
mission 745 nm/785 nm, Perkin Elmer, Waltham,assachusetts). To identify thrombosed and sham- cperated jugular veins, CT venograms were ob-
ained via continuous infusion of iodinated contrast
Isovue-370, Bracco Diagnostics Inc., Princeton,
ew Jersey; rate 55 l/min via tail vein). To enable
ccurate co-registration between FMT and CT
atasets, an imaging cartridge containing the anes-
hetized mouse was placed into a custom-machined
lexiglas holder that supplied isoflurane, warm air,
nd optimal positioning in the CT scanner (Inveon
ET-CT, Siemens, Knoxville, Tennessee). FMT-CT
o-registration was performed by using OsiriX
hareware. Fiducials on the imaging cartridge were
isualized and tagged in FMT and CT images,
llowing point-based co-registration in OsiriX (19).
Fluorescence reﬂectance imaging. Plasma clots,
lood samples, and resected vessels underwent FRI
ith a near-infrared (NIR) filter set (excitation/
mission 740/790 nm; Kodak ImageStation 4000,
arestream Health, Inc., Rochester, New York).
ultiple exposure times (0.1 to 60 s) generated
mages that were exported to 16-bit unscaled TIFF
les for further analysis with ImageJ version 1.44o
Bethesda, Maryland).
Image analyses. Image analyses of IVFM datasets
ere performed by summation of Z stacks into a
-dimensional summation image with ImageJ.
hrombi presented as filling defects on FITC-
extran–generated angiograms. Regions-of-interest
f the thrombus and the adjacent normal vessel were
anually traced (11). Reconstruction and image
nalysis of FMT-CT datasets were performed with
siriX version 3.5.1 software (64 bit) (19). Target-
o-background ratios (TBRs) were calculated by
ividing the mean region-of-interest signal of target
y the mean region-of-interest signal of the back-
round (PBS-treated clot, adjacent vessel, or other
rgans).
Histopathology. After sacrifice, mice were perfused
with 0.9% saline (20 ml) via the left ventricle. For
histopathologic analysis, femoral vessels were ex-
cised and embedded in optimal cutting temperature
compound (Sakura Finetek, Torrance, California).
Serial 6-m cryostat sections were obtained for
uorescence microscopy. Adjacent sections were
tained with hematoxylin and eosin for general
orphology. NIR fluorescence microscopy was per-
ormed on fresh-frozen femoral vein sections using
n upright epifluorescence microscope (Nikon
clipse 90i; Tokyo, Japan). Fluorescence images
ere obtained in the NIR channel for FTP11-Cy7
excitation/emission 710/810 nm; exposure time
0 ms), and FITC channel for autofluorescence (ex-
itation/emission 480/535 nm; exposure time 50 ms).
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610Statistical analysis. Results are expressed as mean 
SEM. Statistical comparisons between 2 groups
were evaluated by using the Mann-Whitney U test
and the Kruskal-Wallis test for multiple groups
followed by the Dunn post-test. Statistical compar-
isons and half-life calculations were performed with
GraphPad Prism. A p value 0.05 was considered
statistically significant.
R E S U L T S
Synthesis of FTP11-Cy7, a NIRF ﬁbrin-imaging
agent. A schematic representation of the FTP11-Cy7
s shown in Figure 1A. The high-performance liquid
hromatography trace demonstrated 98% purity
Fig. 1B). The final product showed a molecular mass of
062 g/mol using matrix-assisted laser desorption/
onization mass spectrometry (Fig. 1C), in agreement
ith the calculated mass. The NIRF signal of the
TP11-Cy7 peptide, as measured by using FRI, related
inearly to its Cy7 concentration at concentrations rele-
ant for imaging (Fig. 1D) (R2  0.99).
In vitro binding assessment of FTP11-Cy7 to human
plasma clots. The binding ability of FTP11-Cy7
as first evaluated in vitro in human FFP clots.
fter 30 min of incubation with individual agents,
Figure 1. Synthesis and Structure of FTP11-Cy7
(A) FTP11-Cy7 is composed of 11 amino acids conjugated to the ne
matography trace demonstrates 98% purity. (C) Matrix-assisted la
of 2062 g/mol. (D) The near-infrared ﬂuorescence signal of the FTP11-CIRF signals were measured by using FRI (Fig. 2).
n vitro clot-binding analyses showed 500% higher
lot TBRs for FTP11-Cy7 compared with control
ree Cy7 (6.3 0.34 vs. 1.2 0.03; p 0.0001). An
excess of unlabeled competitor peptide significantly
blocked binding of FTP11-Cy7 in a dose-dependent
manner (TBR 5.0  0.45 for 10-fold excess, 2.5 
0.34 for 100-fold excess), indicating that the engi-
neered NIRF peptide was clot specific.
Blood half-life of FTP11-Cy7. Blood clearance was
ssessed by serial blood sampling in mice (n  5),
ollowed by measurement of blood NIRF signal
evels with FRI. The NIRF signal decreased rapidly
rom the blood, with a blood half-life of 2.82 min
95% confidence interval: 1.85 to 5.90) (Fig. 3).
High-resolution IVFM of ﬁbrin in femoral DVT. To
determine whether FTP11-Cy7 could enable high-
resolution imaging of fibrin deposition, murine
femoral DVT were imaged by using IVFM. Both
acute DVT (2-h-old) and subacute DVT (3-day-
old) were studied. Thrombi were identified as filling
defects on FITC-dextran angiograms. IVFM dem-
onstrated that NIRF signal increased in both acute
and subacute thrombi (Figs. 4A and 4B). In con-
trast, control free Cy7 did not enhance thrombi
nfrared ﬂuorochrome, Cy7. (B) The high-performance liquid chro-
esorption/ionization mass spectrometry shows a molecular mass
2ar-i
ser dy7 related linearly to its Cy7 concentration (R  0.99).
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611(Fig. 4C). The thrombus TBR was significantly
higher in the FTP11-Cy7 groups (3.5  0.3 for
acute DVT, 2.7  0.5 for subacute DVT; 0.46 
.08 for free Cy7) (Fig. 4D). We also performed in
ivo blocking experiments to evaluate the in vivo
inding specificity of FTP11-Cy7. Pre-injection of
00-fold excess of unlabeled FTP11 blocked the
TP11-Cy7–mediated NIRF signal enhancement
f acute DVT (thrombus TBR 1.6  0.11 vs.
.99  0.04 blocked group; p  0.001) (Fig. 4E).
luorescence microscopy and hematoxylin and eo-
in staining of the histological sections demon-
trated the accumulation of NIRF signal in DVT in
he FTP11-Cy7 group (Figs. 5A and 5B). In
ontrast, control free Cy7 did not enhance thrombi
Fig. 5C).
Noninvasive FMT-CT of FTP11-Cy7 accumulation in
jugular DVT. To image fibrin deposition in DVT
noninvasively, we next performed FMT-CT of
thrombosed jugular veins of mice. The same mice
also possessed a sham-operated contralateral right
jugular vein. To assess FMT signals accurately, we
co-registered fiducially matched jugular veins from FMT
and anatomic CT images (Figs. 6A to 6C). The TBR of
the left jugular DVT was 230% higher than the sham-
operated right jugular vein (mean TBR 3.5  0.7 vs.
1.5  0.3; p  0.05) (Fig. 6D).
After FMT-CT, jugular veins were resected, and
ex vivo FRI was performed. High NIRF signal was
noted in the DVT of the mice (Figs. 7A and 7B).
The TBR of the thrombosed vein was higher than
that of the sham-operated right jugular vein (3.9 
0.4 vs. 2.4  0.4; p  0.05) (Fig. 7C).
D I S C U S S I O N
In this investigation, we demonstrated the following: 1)
the synthesis and specificity validation of a new human
and murine fibrin-targeted imaging agent for in vivo
NIRF imaging; 2) high-resolution, efficient IVFM de-
tection of fibrin deposition, in both acute and subacute
murine DVT; and 3) noninvasive detection of fibrin-rich
jugular DVT using integrated FMT-CT.
The fibrin-targeted NIRF agent is based on the
peptide backbone of EP-2104R (8), an MRI agent
that has successfully undergone Phase II clinical
trials (9,10) and therefore seems attractive for clin-
ical translation. Another favorable capability of the
fibrin-targeted NIRF agent is the ability to detect
thrombi with 20-fold lower injected dose (150
nmol/kg) compared with other MRI-based throm-
bosis imaging agents (4 to 10 mol/kg) (6,10,20).Figure 2. NIRF Imaging of Fibrin in Human Plasma Clots
(A) Clots incubated with FTP11-Cy7 showed a 6-fold increase (p  0.0001)
in near-infrared ﬂuorescence (NIRF) signal enhancement compared with free
Cy7. The NIRF signal was signiﬁcantly blocked with an excess of competitor
peptide in a dose-dependent manner. (B) Representative light and NIRF
images of in vitro binding of FTP11-Cy7 to human plasma clots obtained by
ﬂuorescence reﬂectance imaging. *p  0.05, ***p  0.0001. Bars represent
mean  SE. PBS  phosphate-buffered saline; TBR  target-to-backgroundFigure 3. Clearance of FTP11-Cy7 in Blood Circulation
After injecting FTP11-Cy7 via tail vein in normal C57BL/6 mice, serial blood
sampling was performed through jugular vein. (A) Cy7 levels were measured
by using ﬂuorescence reﬂectance imaging. (B) The blood half-life was 2.8
min (95% conﬁdence interval: 1.85 to 5.90).
ein
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612IVFM enabled high-resolution in vivo detection
of fibrin in both acute and subacute murine DVT,
with significantly greater thrombus-to-background
ratios compared with controls. In vitro and in vivo
blocking studies further demonstrated that FTP11-
Cy7 was thrombus specific. Capitalizing on the
multispectral capabilities of IVFM, fibrin-rich
thrombi were actively detected by FTP11-Cy7
enhancement and passively corroborated by FITC-
dextran angiography. In vivo, the NIRF fibrin-
targeted agent bound to the luminal surface of
thrombus and did not penetrate the deep interior of
the clot, despite its relatively small molecular
weight, consistent with greater thrombus organiza-
tion in the deeper (older) regions of thrombi.
Given these data, the validated NIRF fibrin-
Figure 4. High-Resolution IVFM Detection of Fibrin Deposition
Femoral veins were treated with topical ferric chloride to induce de
intravital ﬂuorescence microscopy (IVFM) of (A) acute DVT or (B) su
mice in each group are shown. Both acute and subacute thrombi w
enhance venous thrombi. (D) The thrombus TBR was signiﬁcantly h
group. (E) FTP11-Cy7 based NIRF signal deposition in acute thromb
FTP11. *p  0.05, **p  0.001. Scale bars, 100 m. FITC  ﬂuorescimaging agent FTP11-Cy7 may prove to be a valuableasset in investigations that aim to track and quantify
fibrinogenesis and fibrinolysis in vivo, especially in
murine model systems. Compared with an antibody-
based imaging agent that required pre-injection (21),
the NIRF fibrin-targeted agent is readily synthesiz-
able, provides good thrombus TBRs in rapid fashion
due its favorable pharmacokinetics, and demon-
strates utility for acute and subacute DVT. In
contrast to other fibrin-imaging agents for in vivo
NIRF molecular imaging of thrombosis (16), the
current peptide-based fibrin agent provides im-
proved thrombus TBRs in subacute thrombi in
addition to acute thrombi, consistent with its
high binding affinity to fibrin (8).
The NIRF fibrin-targeted agent also enabled
noninvasive FMT imaging of fibrin in murine
emoral DVT
vein thrombosis (DVT). After FTP11-Cy7 imaging agent injection,
te DVT was performed. Representative images from multiple
enhanced by FTP11-Cy7. (C) In contrast, control free Cy7 did not
r in the FTP11-Cy7 group compared with the control free Cy7
s blocked by pre-injection of a 100-fold excess of unlabeled
isothiocyanate; V  vein; other abbreviations as in Figure 2.in F
ep
bacu
ere
ighe
i wajugular DVT. FMT is a 3-dimensional, quantitative
how
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613tomographic imaging technique that allows recon-
struction of NIR deep within the body by using an
array of photon detectors and inversion algorithms
Figure 5. Thrombus-Speciﬁc Binding of FTP11-Cy7 in Murine Ve
Fluorescence microscopy and hematoxylin and eosin (H&E) photom
merged image (FITC  Cy7), and H&E are shown in each panel. FT
(C) In contrast, free Cy7 did not bind thrombus. Lower left panel s
Figure 6. Noninvasive Molecular Imaging of Fibrin in Jugular D
In C57BL/6 mice, the left jugular vein was treated with ferric chlorid
puted tomography (FMT-CT) was performed at day 3. (A, B) CT- an
mensional fusion are shown. Arrows indicate a thrombosed left jug
higher than sham-operated jugular veins (*p  0.05) of 9 mice. Other a(12). The addition of CT, similar to integrated
single-photon emission CT or positron emission
tomography–CT systems, allows further co-
s Thrombi
graphs. Fluorescein isothiocyanate (FITC) (green), Cy7 (red),
Cy7 accumulated into both (A) acute and (B) subacute thrombus.
s enlarged thrombosed vein. Scale bars, 100 m.
y Integrated FMT-CT
induce DVT and then ﬂuorescence molecular tomography–com-
T-CT co-registered images of 2-dimensional fusion and (C) 3-di-
vein. (D) The TBR of thrombosed jugular veins was signiﬁcantlynou
icro
P11-VT b
e to
d FM
ularbbreviations as in Figure 4.
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614registration using high-resolution anatomic infor-
mation. In vivo investigations demonstrated the
ability to image fibrin in subacute jugular DVT,
with NIRF signal co-localizing with occluded veins
on CT venography (Fig. 6). Sham surgery–treated
veins demonstrated significantly less NIR fluores-
cence. Modest fibrin signal in the healing incision
was also noted and expected as fibrin formation
occurs during normal wound healing (22). The
ability to track and quantify fibrin deposition non-
invasively in DVT offers the potential to serially
investigate therapies that modulate fibrin within
thrombi, and could provide insights into DVT
resolution and the risk of developing post-
thrombotic syndrome (23,24). From a translational
perspective, larger FMT or optoacoustic systems
scalable to size of the human leg are feasible (25)
and thus may eventually enable clinical NIRF im-
aging of fibrin within DVT. In addition, such
systems could be harnessed to image fibrin content
in carotid plaques to inform stroke risk at baseline
and during carotid arterial intervention (e.g., stent-
ing, endarterectomy).
A more immediate clinically relevant application
of the fibrin-targeted NIRF agent is intravascular
NIRF imaging of fibrin deposition on implanted
coronary stents. Intravascular NIRF imaging is a
new high-resolution strategy to image molecular
and cellular aspects of vascular disease (13,14,26).
Via optimized optical fiber catheters, intravascular
NIRF imaging can provide high-resolution, sensi-
tive readouts of molecular targets in coronary-sized
vessels through blood, without the need for flush-
ing, due to relatively low blood attenuation of NIR
light. In the future, the ability to image fibrin on
healing coronary stents may offer new insights into the
Figure 7. Ex Vivo Targeting of FTP11-Cy7 to Thrombosed Jugul
(A) Fluorescence reﬂectance image of Cy7 channel and (B) ex vivo
matched to the thrombosed lesion. (C) The thrombus TBR of the le
right jugular vein (*p  0.05) in 9 mice. Arrows indicate a thrombopathogenesis of stent thrombosis, particularly late fstent thrombosis in current and next-generation drug-
eluting stents, especially when coupled with high-
resolution structural imaging via intravascular ul-
trasound (14) or via single catheters integrating
NIRF with optical frequency domain imaging
(27), a leading modality for imaging coronary
stent architecture.
Study limitations. The free cyanine dye (free Cy7)
nd unlabeled competing FTP11 peptide were used
s controls in all experiments. Although a peptide-
ased control agent (e.g., scrambled peptide-Cy7)
ould have additionally been used, previous publi-
ations have validated the specificity of the fibrin-
argeting peptide backbone (FTP11) used in this
tudy (5-8,10). Higher blocking peptide concentra-
ions could provide greater blocking effects. In
ddition, dose- and time-optimization experiments
f FTP11-Cy7 could yield higher thrombus TBRs
han currently achieved.
C O N C L U S I O N S
A new synthesized NIRF fibrin-targeted peptide was
found to avidly and specifically bind murine and
human thrombi, and enable sensitive, fast multimodal
intravital and noninvasive optical imaging detection of
acute and subacute murine DVT in vivo.
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